T he intrarenal renin-angiotensin system (RAS) is separate from the peripheral RAS and contributes independently to the regulation of blood pressure and sodium excretion. [1] [2] [3] [4] All of the precursors of angiotensin peptide synthesis are located within the renal proximal tubule (RPT), including angiotensinogen, renin, and angiotensin converting-enzyme mRNA. [5] [6] [7] [8] Interstitial fluid concentrations of angiotensin II (Ang II) and angiotensin III (Ang III) are far greater (nanomolar) than can be explained solely on the basis of equilibration with circulating concentrations (femtomolar). 9, 10 These findings suggest that important influences are exerted by locally generated angiotensins. Additionally, the 2 major receptor subtypes that mediate actions of RAS, the angiotensin type-1 receptor (AT 1 R) and the angiotensin type-2 receptor (AT 2 R), are both present in RPT cells, consistent with a primary role for tubular angiotensins as paracrine substances in the control of renal function. 11, 12 The enzymes responsible for the metabolism of Ang II are also highly expressed in the kidney. Aminopeptidase A (APA), a membrane-bound zinc-dependent aminopeptidase, is distributed at the surface of glomerular endothelial and mesangial cells and podocytes and all along the nephron, with highest expression in the RPT. 13, 14 As shown in Figure 1 , APA preferentially cleaves the N-terminal acidic amino acid (aspartate) from Ang II to generate Ang III, which serves as the rate-limiting step in Ang II metabolism. 15 Aminopeptidase N (APN) is also a membrane-bound, zinc-dependent aminopeptidase and is a major constituent of RPT cell brush border membranes. 16, 17 The metabolism of Ang III to Ang IV is mediated by APN, which preferentially releases neutral amino acids from the N-terminal end of oligopeptides. 18 Specific pharmacological inhibitors of APA and APN have been used to elucidate the role of Ang II and Ang III within local tissue RAS. Selective APA inhibitor, EC-33 (3-amino-4-thio-butyl-sulfonic acid, inhibition constant K i ϭ0.29 mol/ L), blocks the conversion of Ang II to Ang III and increases the half-life of Ang II by 2.6-fold. 19 Similarly, the selective APN inhibitor, PC-18 (2-amino-4-methylysulfonyl-butane thiol, K i ϭ8.0 nmol/L), blocks the conversion of Ang III to Ang IV, and increases the half-life of Ang III by 3.9-fold. 20 We have previously reported that renal interstitial (RI) Ang III infusion, but not Ang II infusion, results in natriuresis mediated by the AT 2 R when AT 1 Rs are blocked systemically. 21 This response can be significantly augmented during concomitant infusion of PC-18, 22 via accumulation of unmetabolized Ang III. In the present set of studies, we sought to determine whether conversion of Ang II to Ang III was critical for AT 2 R-mediated natriuresis. We evaluated renal sodium excretion rate (U Na V) in response to RI infusion of Ang II with PC-18 to determine whether intrarenal APN inhibition would convert the absence of a natriuretic response to Ang II (without APN inhibition) into a robust natriuretic response because of accumulation of Ang III. Additionally, we determined whether coinhibition of APA would abolish the natriuretic response to Ang II enabled by APN inhibition.
Methods

Animal Preparation
The experiments, which were approved by the University of Virginia Animal Research Committee, were conducted in 12-week-old 250-g female Sprague-Dawley rats (Harlan, Teklad). All of the studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were placed under general anesthesia with pentobarbital (50 mg/mL) given 5 mg/100 g body weight intraperitoneally, which resulted in deep anesthesia for control and 4 experimental periods (30 minutes each). A tracheostomy was performed in all of the rats, and arterial access was achieved by direct cannulation of the right carotid artery. Intravenous access was obtained via cannulation of the right internal jugular vein in each rat. Rats were housed under controlled conditions (temperature: 21Ϯ1°C; humidity: 60Ϯ10%; and light: 8:00 to 20:00). Experiments were initiated at the same time each day to prevent any diurnal variation in blood pressure (BP).
Renal Cortical Interstitial Infusion
The renal interstitial route of administration was used in these studies to eliminate systemic hemodynamic factors that may play a role in the natriuretic response. After a midline incision, an open-bore microinfusion catheter (PE-10) was inserted into the cortex of the kidney at 0.2 cm to access the cortical interstitial space for RI infusion of either pharmacological agent or vehicle at 2.5 L/min. All pharmacological agents were prepared in 5% dextrose in water (D 5 W). A small amount of Vetabond tissue adhesive was added to the insertion site(s) to prevent accidental dislodging and any pressure loss in the kidney. The infusion catheters were connected to a Harvard pump 5522, and substances were infused directly into the renal cortical interstitial (RI) compartment. When 2 pharmacological agents were used, they were combined and coinfused into the RI space through the same microinfusion catheter. RI infusions at the rates used in these experiments do not affect RI hydrostatic pressures (data not shown).
BP Measurements
Mean arterial BP (MAP) was measured by the direct intracarotid method with the use of a digital BP analyzer (Micromed Inc). MAPs were recorded every 5 minutes and averaged for each of the control and experimental periods.
Pharmacological Agents
Ang II (Bachem), an AT 1 Rats were studied on normal Na ϩ intake with both kidneys intact. Using sterile technique, osmotic minipumps were implanted into the interscapular region with the animals under short-term anesthesia with ketamine (100 mg/mL) and xylazine (20 mg/mL) for candesartan (CAND) (0.01 mg/kg per minute) infusion 24 hours before and during the experiment. The right kidney was infused with vehicle (5% dextrose in water, D 5 W) directly into the RI space during both control and experimental collection periods (30 minutes each) and served as the control kidney in all studies. In the first set of animals (nϭ6), Ang II (3.5, 7, 14, and 28 nmol/kg per minute) was infused cumulatively into the RI space of the left (experimental) kidney after a 30 minute control infusion of D 5 W (2.5 L/min). In the second set of animals (nϭ8), Ang II (3.5, 7, 14, and 28 nmol/kg per minute) plus PC-18 (25 g/min) was infused cumulatively into the RI space of the left (experimental) kidney after a 30-minute control infusion of (D 5 W) (2.5 L/min). Both ureters were cannulated individually to collect urine for quantification of U Na V for the control and 4 experimental periods (each 30 minutes) from both the right (control) and left (experimental) kidneys.
Effects of RI Ang II؉PC-18؉PD in the Presence of Systemic AT 1 R Blockade
Rats (nϭ6) were prepared identically to those described above, but instead of Ang IIϩPC-18 infusion into the left kidney, Ang IIϩPC-18ϩPD (10 g/kg/min) was infused. The right kidney continued to be infused with vehicle into the renal interstitial space during both control and experimental periods. U Na V was determined for control and experimental periods from both the left and right kidneys.
Effects of Unilateral RI Ang II؉PC-18؉EC-33 on U Na V in Rats on Normal Na
؉ Intake in the Presence of Systemic AT 1 R Blockade Rats (nϭ8) were prepared identically to those described above, except that the left kidney was infused with Ang IIϩPC-18ϩEC-33 (25 g/min) into the cortical interstitial space, whereas the right kidney continued to be infused with vehicle during both control and experimental periods. U Na V was determined for control and experimental periods from both the left and right kidneys.
Statistical Analysis
Comparisons among vehicle, AT 1 R blocker (CAND), AT 2 R blocker (PD), Ang II, PC-18 (APN inhibitor), and EC-33 (APA inhibitor) were estimated by ANOVA, including a repeated-measures term, by using the general linear models procedure of the Statistical Analysis System. Multiple comparisons of individual pairs of effect means were conducted by the use of least-square means pooled variance. Data are expressed as meanϮ1 SE. Statistical significance was identified at a level of PϽ0.05. 
Blood Pressure Responses to Renal Interstitial Ang II, Ang II؉PC-18, Ang II؉PC-18؉PD, and Ang II؉PC-18؉EC-33 Infusions in Rats on Normal Sodium Intake in the Presence of Systemic AT 1 R Blockade
As shown in Figure 5 , compared with time control during which only vehicle was infused, each RI infusion did not alter 
Discussion
These studies demonstrate that RI Ang II, an AT 2 R ligand, does not induce a natriuresis in the presence of systemic AT 1 R blockade. However, a natriuretic response to Ang II, mediated by the AT 2 R, is unmasked by the intrarenal addition of PC-18, an APN inhibitor. Because the metabolism of Ang III to Ang IV by APN is inhibited by PC-18, these data suggest that Ang III is a significant mediator of Ang IIinduced natriuresis. This conclusion is further supported by the ability of APA inhibition to abolish the natriuretic response to Ang IIϩPC-18.
Previous studies from our laboratory have shown that in the presence of AT 1 R blockade, RI Ang III infusion results in natriuresis that is abolished by concomitant PD infusion, implicating the renal AT 2 R in the response. 21 Furthermore, addition of RI PC-18 to Ang III infusion causes a 1.8-to 2.8-fold increase in Na ϩ excretion compared with RI Ang III infusion alone. 22 These findings prompted the present set of investigations to determine whether renal conversion of Ang II to Ang III was necessary for the natriuretic response.
In local renin-angiotensin systems (RASs), Ang III has been shown to be a major effector peptide. In the brain, Ang III, and not Ang II, is the agonist responsible for mediating vasoconstriction and BP elevation via the AT 1 R. 15, [23] [24] [25] [26] [27] Ang III was also shown to mediate vasopressin release when administered directly into the 3rd ventricle of the brain. 15, 27 Similarly, in the adrenal RAS, aldosterone production is stimulated by Ang III as well as Ang II. 28 In the intrarenal RAS, Ang III has been reported to increase angiotensinogen levels, sodium excretion, transforming growth factor (TGF)-␤, fibronectin, and monocyte chemoattractant protein-1 gene expression. 21, 29, 30 The relative affinities of Ang II and Ang III for AT 1 Rs and AT 2 Rs remain a topic of interest. Some authors argue that Ang III binds mainly to AT 2 Rs and exhibits a lower affinity for AT 1 Rs compared with that of Ang II. 31 In the myometrial cells of the pig uterus, the K i for Ang III at the AT 2 R is 2.2Ϯ0.2 nmol/L, and in rat liver membranes, the K i for Ang III at the AT 1 R is 10.5Ϯ0.3 nmol/L, corroborating this observation. However, in the brain, Ang II and Ang III have been noted to display similar affinities for AT 1 Rs and AT 2 Rs, 32, 33 suggesting that local tissue RAS systems may behave differently. The specific affinities of Ang II and Ang III for AT 1 Rs and AT 2 Rs have not been studied systematically in the kidney. However, previous studies from our laboratory have demonstrated that RI infusion of Ang III causes a significant natriuresis in the presence of systemic AT 1 R blockade, which is abolished by the addition of PD. Thus, within the intrarenal RAS, Ang III is capable of exerting significant actions at AT 2 Rs, at least in the presence of AT 1 receptor blockade. 21 APA is the major enzyme responsible for the metabolism of Ang II to Ang III 13, 14 and is most highly expressed in the RPT. 13,14 APN, the major renal enzyme responsible for the cleavage of Ang III to Ang IV, 15 is also expressed on the brush border (apical) membranes of RPT cells and enterocytes. 34 The APA inhibitor EC-33 exhibits an inhibitory potency nearly 100-fold greater for APA (K i ϭ0.29 mol/L) than for APN (K i ϭ25 mol/L), 35 whereas the inhibitory potency of PC-18 is 2150-and 125-fold more active on APN (K i ϭ0.008Ϯ0.001 mol/L) than on APA (K i ϭ17.2Ϯ4.3 mol/ L). 36 -38 In the systemic circulation, Ang III is metabolized 2 to 4 times more rapidly than Ang II, accounting for a reduced relative efficacy of systemically infused Ang III. 28, 34 Thus, the infusion of PC-18 directly into the RI compartment in the present study allowed for examination of the effects mediated by Ang III at the local intrarenal tissue RAS, with the advantage of permitting this rapidly degraded peptide to remain available for a longer period of time.
It is possible that PC-18 inhibition of APN, although quite specific, may have permitted accumulation of other intrarenal peptides that are metabolized by APN (eg, kallidin), accounting for the natriuretic response observed to Ang II in the present study. However, the effects of the other substrates of APN would also have been mediated by the renal AT 2 R, given that the natriuresis enabled by the addition of PC-18 to Ang II, was abolished by the coinfusion of PD, a specific AT 2 R. Interestingly, the highest Ang II infusion rate (28 nmol/kg/min), when combined with PC-18, resulted in less of an increase in U Na V, compared with lower Ang II infusion rates (eg, 7 nmol/kg/min). One possible explanation is that APA becomes "saturated" during the higher concentrations of Ang II infusion, resulting in decreased Ang III formation and thereby decreased natriuresis via the unblocked AT 2 R.
Inhibition of APA with EC-33 likely permitted the accumulation of Ang II, which is known to have antinatriuretic effects via the AT 1 R. 39 -41 We believe the inhibition of natriuresis observed during Ang IIϩPC-18ϩEC-33 infusion was more likely attributable to the decreased availability of Ang III, rather than antinatriuretic effects of Ang II, given that the AT 1 R was blocked for 24 hours before and during our studies. The adequacy of AT 1 R blockade was confirmed by the absence of significant MAP increases in response to renal interstitial Ang II infusion and Ang IIϩPC-18ϩEC-33 infusion, when unmetabolized Ang II likely accumulated. Furthermore, the addition of EC-33 to renal interstitial Ang IIϩPC-18 infusion may have shunted the Ang II degradation pathway toward Ang 1-7 formation via ACE-2. Renally infused Ang 1-7 has been reported to induce natriuresis in some studies, [42] [43] [44] whereas others argue that renal tubular sodium reabsorption may be stimulated by Ang 1-7. [45] [46] [47] In the present study, Ang IIϩPC-18ϩEC-33 infusion, with presumed accumulation of Ang 1-7, did not result in significant natriuresis.
The addition of PD, a selective AT 2 R antagonist, completely eliminated the natriuretic response observed with Ang IIϩPC-18 back to control levels, indicating that the renal AT 2 R was largely responsible for the natriuresis. AT 2 Rs have been implicated in the natriuresis of both normal and diseased rodents. In obese Zucker rats, AT 1 R blockade induces natriuresis to a greater degree than in lean rats and the natriuresis is abolished with AT 2 R blocker PD. 48 In streptozotocininduced diabetes mellitus, the rise in fractional sodium excretion is inhibited by administration of PD in the absence of exogenous hormone, suggesting a tubular action of AT 2 R blockade. 49 In both disease models, AT 2 Rs are markedly upregulated in RPT cell basolateral and brush border membranes compared with lean or nondiabetic controls. 48, 49 However, the preferred effector ligand of AT 2 R-mediated natriuresis has not been established in disease models, and the specific mechanisms of normal Ang III-induced natriuresis via the renal AT 2 R have not yet been elucidated.
Perspectives
The present studies demonstrate that in the presence of systemic AT 1 R blockade, RI administration of PC-18, a potent inhibitor of the enzyme which converts Ang III to Ang IV, enables a natriuretic response to RI infusion of Ang II alone, and that this response is blocked when Ang II is not able to be converted to Ang III. These studies indicate that Ang III is the major agonist of AT 2 R-induced natriuresis. Our results suggest that Ang III, the AT 2 R, APA, and APN are potentially important therapeutic targets for disorders characterized by Na ϩ and fluid retention, such as hypertension and congestive heart failure.
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